Form 4: TriSalus Life Sciences Director Sean Murphy Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director Sean Murphy was granted 15,000 stock options with an exercise price of $5.50, increasing his total beneficial ownership of derivative securities to 554,681.

Summary

• Sean Murphy, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options on June 12, 2025.
• The exercise price for these options is $5.50 per share.
• The options are set to expire on June 11, 2035.
• The shares subject to the option will fully vest on the one-year anniversary of the grant date (June 12, 2025), or in any case, on the date of the Issuer's next annual stockholder meeting, provided Mr. Murphy continues his service with the Issuer.
• Following this transaction, Mr. Murphy's total beneficial ownership of derivative securities in TriSalus Life Sciences, Inc. stands at 554,681.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. It's a routine compensation event, not indicative of major operational changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The vesting schedule for the granted options indicates an expectation of continued service from Director Sean Murphy, aligning his future incentives with the company's performance.

Industry Context

The granting of stock options to directors is a common practice in the life sciences and broader corporate sectors, serving as a key component of executive and director compensation packages designed to align their interests with long-term shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard form of equity compensation for directors across various industries, including biotechnology and pharmaceuticals, similar to practices at companies like Gilead Sciences or Amgen.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity awards, ensuring retention and commitment.
• The exercise price of $5.50 is a specific value tied to the grant date, which is a common method for pricing options.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The options will vest on the one-year anniversary of the grant date (June 12, 2025) or the date of the Issuer's next annual stockholder meeting, subject to continued service.
• Sean Murphy may exercise the vested options at the specified exercise price before the expiration date of June 11, 2035.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, SEC Form 4, Stock Option Grant, Director Compensation, Beneficial Ownership, Insider Transaction, Equity Compensation, Sean Murphy